Indazolyl-oxo-isothiazole compounds

1. A compound represented by Formula (I) below, or a pharmaceutically acceptable salt thereof or a solvate of these:

wherein the formula, R 1 represents a group arbitrarily selected from a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group and a C 6-14 arylcarbonyl group,

R 2 represents a group arbitrarily selected from a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a C 7-20 aralkyl group, a heteroaryl C 1-6 alkyl group, a C 6-14 aryloxy C 1-6 alkyl group and a heteroaryloxy C 1-6 alkyl group,

R 3 represents a group arbitrarily selected from a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group and a cyano group,

R 4 represents a group arbitrarily selected from a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group and a cyano group,

each of R 1 R 2 and R 3 is optionally substituted with 1 to 5 of R 5 ,

each R 5 independently represents a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 1-6 alkoxycarbonyl group, a —NR b R c group (in which each of R b and R c independently represents a hydrogen atom, a C 1-6 alkyl group or a non-aromatic heterocyclic group), a mono/di-C 1-6 alkylamino C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, non-aromatic heterocyclic group, heteroaryl group, a C 3-8 cycloalkyl C 1-6 alkyl group, a C 7-20 aralkyl group, non-aromatic heterocyclic C 1-6 alkyl group, a heteroaryl C 1-6 alkyl group, a C 6-14 aryloxy group, heteroaryloxy group, a C 7-20 aralkyloxy group and a heteroaryl C 1-6 alkyloxy group,

each of the C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, C 6-14 aryl group, non-aromatic heterocyclic group, heteroaryl group, C 3-8 cycloalkyl C 1-6 alkyl group, C 7-20 aralkyl group, non-aromatic heterocyclic C 1-6 alkyl group, heteroaryl C 1-6 alkyl group,C 6-14 aryloxy group, heteroaryloxy group, C 7-20 aralkyloxy group or heteroaryl C 1-6 alkyloxy group in R 5 is optionally substituted with 1 to 5 of a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a cyano group, a C 1-6 alkoxycarbonyl group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group (which is itself optionally substituted with 1 to 5 C 1-6 alkyl groups), a non-aromatic heterocyclic group and a heteroaryl group,

R 2 may bind with R 1 or R 3 to form a fused ring group together with part of a pyrazole ring, and this fused ring group is a 5- to 10-member heterocyclic group or C 6-10 aryl group optionally substituted with 1 to 5 of R 6 ,

each R 6 independently represents a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 1-6 alkoxycarbonyl group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a C 3-8 cycloalkyl C 1-6 alkyl group, a C 7-20 aralkyl group, a heteroaryl C 1-6 alkyl group, aC 6-14 aryloxy group, a heteroaryloxy group, a C 7-20 aralkyloxy group and a heteroaryl C 1-6 alkyloxy group,

each R 6 is optionally substituted with 1 to 5 of R 7 ,

each R 7 independently represents a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a C 1-6 alkoxy C 1-6 alkyl group, a cyano group, a C 1-6 alkoxycarbonyl group, a —CONR d R e group (in which each of R d and R e independently represents a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group or a C 6-14 aryl group), a mono/di-C 2-7 alkanoylamino group, an amino group, a mono/di-C 1-6 alkylamino group, a mono/di-C 1-6 alkylamino C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a C 3-8 cycloalkyl C 1-6 alkyl group, a C 7-20 aralkyl group, a non-aromatic heterocyclic C 1-6 alkyl group, a heteroaryl C 1-6 alkyl group, a C 6-14 aryloxy group, heteroaryloxy group, a C 3-8 cycloalkylcarbonyl group, a group, a C 6-14 arylcarbonyl group and a non-aromatic heterocyclic carbonyl group, and

each of the C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, C 6-14 aryl group, non-aromatic heterocyclic group, heteroaryl group, C 3-8 cycloalkyl C 1-6 alkyl group, C 7-20 aralkyl group, non-aromatic heterocyclic C 1-6 alkyl group, heteroaryl C 1-6 alkyl group, C 6-14 aryloxy group, heteroaryloxy group, C 3-8 cycloalkylcarbonyl group, C 6-14 arylcarbonyl group or non-aromatic heterocyclic carbonyl group of R 7 is optionally substituted with 1 to 5 of a halogen atom, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group or a C 1-6 alkoxy C 1-6 alkyl group.

2. The compound represented by Formula (I)-1 below or a pharmaceutically acceptable salt thereof or a solvate of these according to claim 1 :

wherein the formula, R 1a a represents a group arbitrarily selected from a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 3-8 cycloalkyl group and a C 6-14 arylcarbonyl group,

each R 1a is optionally substituted with 1 to 5 halogen atoms,

each R 6a independently represents a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a cyano group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a C 6-14 aryloxy group, a heteroaryloxy group, a C 7-20 aralkyloxy group and a heteroaryl C 1-6 alkyloxy group,

each R 6a is optionally substituted with 1 to 5 of R 7a ,

each R 7a independently represents a group arbitrarily selected from a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a C 2-6 alkenyloxy group, a C 2-6 alkynyloxy group, a C 1-6 alkoxy C 1-6 alkyl group, a cyano group, a C 1-6 alkoxycarbonyl group, a —CONR d R e group (in which each of R d and R e independently represents a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group or a C 6-14 aryl group), a mono/di-C 2-7 alkanoylamino group, an amino group, a mono/di-C 1-6 alkylamino group, a C 3-8 cycloalkyl group, a C 6-14 aryl group, a non-aromatic heterocyclic group, a heteroaryl group, a C 3-8 cycloalkyl C 1-6 alkyl group, a C 7-20 aralkyl group, a non-aromatic heterocyclic C 1-6 alkyl group, a heteroaryl C 1-6 alkyl group, a C 6-14 aryloxy group, a heteroaryloxy group, a C 3-8 cycloalkylcarbonyl group, a C 6-14 arylcarbonyl group and a non-aromatic heterocyclic carbonyl group, and

the C 3-8 cycloalkyl group, non-aromatic heterocyclic group, C 3-8 cycloalkyl C 1-6 alkyl group, non-aromatic heterocyclic C 1-6 alkyl group, C 6-14 aryloxy group, C 3-8 cycloalkylcarbonyl group, C 6-14 arylcarbonyl group or non-aromatic heterocyclic carbonyl group in each R 7a is optionally substituted with 1 to 5 halogen atoms, C 1-6 alkyl groups, halogenated C 1-6 alkyl groups, C 1-6 alkoxy groups or C 1-6 alkoxy C 1-6 alkyl groups, and n represents 0, 1 or 2.

3. A compound, a pharmaceutically acceptable salt, a solvate or an optical isomer thereof selected from the following structures:

4. A compound which is selected from:

5-(indazol-1-yl)-1-oxo-1,2-thiazol-3-ol,

5-(5-bromoindazol-1-yl)-1-oxo-1,2-thiazol-3-ol,

5-[5-(2-methoxypyridin-4-yl) indazol-1-yl]-1-oxo-1,2-thiazol-3-ol,

5-[5-(6-cyclopropylpyridin-3-yl) indazol-1-yl]-1-oxo-1,2-thiazol-3-ol,

5-[5-(4-methyl-2, 3-dihydropyrido[3,2-b][1, 4]oxazin-7-yl)indazol-1-yl]-1-oxo-1,2-thiazol-3-ol,

or a pharmaceutically acceptable salt thereof or a solvate of these, or an optical isomer of these.

5. 5-(indazol-1-yl)-1-oxo-1,2-thiazol-3-ol, or a pharmaceutically acceptable salt, a solvate or an optical isomer thereof.

6. 5-(5-bromoindazol-1-yl)-1-oxo-1,2-thiazol-3-ol, or a pharmaceutically acceptable salt, a solvate or an optical isomer thereof.

7. 5- [5-(2-methoxypyridin-4-yl) indazol-1-yl]-1-oxo-1,2-thiazol-3-ol, or a pharmaceutically acceptable salt, a solvate or an optical isomer thereof.

8. 5-[5-(6-cyclopropylpyridin-3-yl) indazol-1-yl]-1-oxo-1,2-thiazol-3-ol, or a pharmaceutically acceptable salt, a solvate or an optical isomer thereof.

9. 5-[5-(4-methyl 2, 3-dihydropyrido[3,2-b][1, 4]oxazin-7-yl)indazol-1-yl]-1-oxo-1,2-thiazol-3-ol, or a pharmaceutically acceptable salt, a solvate or an optical isomer thereof.

10. A pharmaceutical composition containing as an active ingredient at least one of the compound or a pharmaceutically acceptable salt, or a solvate thereof according to claim 1 , and a pharmaceutically acceptable carrier or excipient.

11. A pharmaceutical composition containing as an active ingredient at least one of the compound or a pharmaceutically acceptable salt or a solvate thereof according to claim 2 , and a pharmaceutically acceptable carrier or excipient.

12. A pharmaceutical composition containing as an active ingredient at least one of the compound or a pharmaceutically acceptable salt or a solvate thereof according to claim 3 , and a pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition containing as an active ingredient at least one of the compound or a pharmaceutically acceptable salt or a solvate thereof according to claim 4 , and a pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition containing as an active ingredient at least the compound, a pharmaceutically acceptable salt or solvate thereof according to claim 5 , and a pharmaceutically acceptable carrier or excipient.

15. A pharmaceutical composition containing as an active ingredient at least the compound, a pharmaceutically acceptable salt or solvate thereof according to claim 6 , and a pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition containing as an active ingredient at least the compound, a pharmaceutically acceptable salt or solvate thereof according to claim 7 , and a pharmaceutically acceptable carrier or excipient.

17. A pharmaceutical composition containing as an active ingredient at least the compound, a pharmaceutically acceptable salt or solvate thereof according to claim 8 , and a pharmaceutically acceptable carrier or excipient.

18. A pharmaceutical composition containing as an active ingredient at least the compound, a pharmaceutically acceptable salt or solvate thereof according to claim 9 , and a pharmaceutically acceptable carrier or excipient.